The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Updated JULIET results for tisagenlecleucel in DLBCL
JULIET is a single-armed, open-label, global, multicenter pivoral Phase II trial (NCT02445248) of the CD19-directed CAR T-cell product tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), in which the primary objective was met at the interim analysis. Here, Richard Thomas Maziarz, MD, of Knight Cancer Institute, Oregon Health & Science University, Portland, OR, presents an updated analysis of the JULIET trial, with a median of 19 months follow-up. These exciting results demonstrate sustained activity in this patient population with high response rates and durable responses. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
